

433

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
19 October 2006 (19.10.2006)

PCT

(10) International Publication Number  
WO 2006/108666 A1

(51) International Patent Classification:

A61K 31/4709 (2006.01) A61P 25/06 (2006.01)  
A61K 31/4725 (2006.01) A61P 25/28 (2006.01)  
A61P 17/06 (2006.01)

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(21) International Application Number:

PCT/EP2006/003437

(22) International Filing Date: 13 April 2006 (13.04.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data: 60/670,648 13 April 2005 (13.04.2005) US

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (for all designated States except US): PROTEOSYS AG [DE/DE]; Carl-Zeiss-Strasse 51, 55129 Mainz (DE).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(72) Inventor; and

(75) Inventor/Applicant (for US only): SCHRATTENHOLZ, André [DE/DE]; Hinter der Kirche 43, 55129 Mainz (DE).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(74) Agent: WEICKMANN & WEICKMANN; Postfach 860 820, 81635 München (DE).



WO 2006/108666 A1

(54) Title: MEFLOQUINE, NELFINAVIR AND SAQUINAVIR AS NOVEL AGENTS FOR NEURODEGENERATIVE AND (NEURO-) INFLAMMATORY DISEASES

(57) Abstract: The present invention generally relates to the neuroprotective, anti-apoptotic and anti-inflammatory activity of mefloquine, nelfinavir and saquinavir and derivatives thereof based on recently discovered interactions with prohibitin and estrogen receptors and the inhibition of mitochondrial voltage-dependent anion channel 1. Thus, mefloquine, nelfinavir and saquinavir and derivatives thereof may be used as medicaments for the prevention and/or treatment of neurodegenerative and inflammatory, particularly neuroinflammatory diseases.

- 1 -

**Mefloquine, Nelfinavir and Saquinavir as novel agents for neurodegenerative and (neuro-) inflammatory diseases**


**Description**

The present invention generally relates to the neuroprotective, anti-apoptotic and anti-inflammatory activity of mefloquine, nelfinavir and saquinavir and derivatives thereof based on recently discovered interactions with prohibitin and estrogen receptors and the inhibition of mitochondrial voltage-dependent anion channel 1. Thus, mefloquine, nelfinavir and saquinavir and derivatives thereof may be used as medicaments for the prevention and/or treatment of neurodegenerative and inflammatory, particularly neuroinflammatory diseases.

Nelfinavir (Viracept®) and saquinavir (Invirase® or Fortovase®) are known as anti-HIV drugs called HIV protease inhibitors. Further HIV protease inhibitors of the same class of compounds are amprenavir (Agenerase®), indinavir (Crixivan®), lopinavir (Kaletra®), ritonavir (Norvir®) and atazanavir (Reyataz®). These compounds are used for treatment of HIV.

Nelfinavir is usually administered in the form of (3S-(2(2S\*,3S\*), 3 $\alpha$ ,4 $\alpha$ ,8 $\alpha$ )))-N-(1,1-dimethylethyl)decahydro-2-(2-hydroxy-3-((3-hydroxy-2-methylbenzoyl)amino)-4-(phenylthio)butyl)-3-isoquinolinecarboxamide; The compound, its manufacture, its mechanism of action and its clinical efficacy have been described in the state of the art.

- 2 -




Nelfinavir

Saquinavir is usually administered in the form of Saquinavir mesylate (S)-N-  
 (( $\alpha$ S)- $\alpha$ -((1R)-2-((3S,4aS,8aS)-3-(tert-butylcarbamoyl)octahydro-2(1H)-  
 5 isoquinolyl)-1-hydroxyethyl) phenethyl)-2-quinaldamidossuccinamide mono-  
 methanesulfonate (salt); DRG-0164; Fortovase<sup>®</sup>; Invirase<sup>®</sup>; Ro 31-8959/003;  
 Saquinavir monomethanesulfonate salt; butanediamide, N(sup 1)-(3-(3-  
 (((1,1-dimethylethyl)amino) carbonyl)octahydro-2(1H)-isoquinoliny)-2-  
 hydroxy-1- (phenylmethyl)propyl)-2-((2-quinoliny-carbonyl)amino)-, (3S-(2  
 10 (1R\*(R\*),2S\*),3 $\alpha$ ,4a $\beta$ ,8a $\beta$ )-, monomethanesulfonate (salt); N-[1-benzyl-2-  
 hydroxy-3-[[3-(tert-butylcarbamoyl)-1,2,3,4,4a,5, 6,7,8,8a-  
 decahydroisoquinol-2-yl]]propyl]-2-(2- quinolylcarbonylamino)succinamide;  
 methanesulfonic acid. The compound, its manufacture, its mechanism of  
 action and its clinical efficacy have been described in the state of the art.

15

- 3 -



Saquinavir

The assumed antiapoptotic properties of this class of compounds have already been disclosed (Badley A. D. In vitro and in vivo effects of HIV protease inhibitors on apoptosis. *Cell Death Differ.* (2005) Mar 11; [Epub ahead of print]; Phenix B. N., Lum J.J., Nie Z., Sanchez-Dardon J., and Badley A. D., Antiapoptotic mechanism of HIV protease inhibitors: preventing mitochondrial transmembrane potential loss; *Blood.* 98, 1078-1085 (2001)).

10

Mefloquine (Lariam<sup>®</sup>) is known as an anti-malaria drug which has high efficacy in treating the widespread chloroquine-resistant *Plasmodium falciparum* strains. Mefloquine is used both for prophylaxis and treatment of malaria and is relatively well tolerated.

15

Mefloquine is usually administered in the form of mefloquine hydrochloride (*R\*,S\**)-(+)- $\alpha$ -2-piperidiny-2,8-bis(trifluoromethyl)-4-quinolinemethanol monohydrochloride; DL-erythro- $\alpha$ -2-piperidyl-2,8-bis(trifluoromethyl)-4-quinolinemethanol monohydrochloride; WR-142490; Ro-21-5998; Lariam<sup>®</sup>.  $C_{17}H_{17}ClF_6N_2O$ ; mol wt 414.78. C 49.23%, H 4.13%, Cl 8.55%, F 27.48%, N 6.75%, O 3.86%. The compound, its manufacture, its mechanism of action and its clinical efficacy have been described extensively in C. J. Ohnmacht

20

- 4 -

et al. *J. Med. Chem.* 14, 926 (1971); DE patent 28 06 909, CA. 90, 22838q (1979); U.S. patent 4,507,482; J. T. Blackwell, *J. Med. Chem.* 17, 210 (1974); M. W. Davidson *et al.*, *J. Med. Chem.* 20, 1117 (1977); R. E. Brown *et al.*, *Life Sci.* 25, 1857 (1979); Photochemistry: G. A. Epling, U. C. Yoon, *Chem. Letters* 1982 (2), 211; Pharmacokinetics: D. E. Schwartz *et al.*, *Chemotherapy (Basel)* 28, 70 (1982). HPLC determination: 1. M. Kapetanovic *et al.*, *J. Chromatog.* 277, 209 (1983); G. M. Trenholme *et al.*, *Science* 190, 792 (1975); F. Tin *et al.* *Bull. WHO* 60, 913 (1982); J. M. Kofe Ekue *et al.*, *ibid.* 61, 713 (1983); J.-M. de Souza *ibid.* 809, 815 and P. Lim in *Analytical Profiles of Drug Substances* vol. 14, K. Florey, Ed. (Academic Press, New York, 1985) pp 157-180 (all citations from Merck Index, 12<sup>th</sup> edition, 1996).

The relatively new antimalarial mefloquine (Lariam<sup>®</sup>) has become extremely popular due to its efficacy in treating the wide-spread chloroquine-resistant *Plasmodium falciparum* strains. Mefloquine is known both for severe neurologic and psychiatric adverse effects associated with its use.

There have also been reports about neurotoxic effects of mefloquine at higher dosages (Rendi-Wagner P. *et al.*, *Acta Trop.* 81, 167-173 (2002). The mechanisms of these adverse effects are discussed controversially in the literature. Toxic encephalopathy appears to be one of the serious neurological manifestations which is slowly reversible depending on individual predisposition. Self-administration schemes can be therefore both most useful and dangerous due to expected benefits and potential risks. (Nicolas X. *et al.*, *Presse Med.* 30, 1349-1350 (2001); Dow G. S. *et al.*, *Antimicrob. Agents Chemother.* 48, 2624-2632 (2004). There are indications that disruption of neuronal calcium homeostasis can induce an ER stress response at physiologically relevant concentrations, thus contributing to the neurotoxicity of the drug in vitro (Dow G. S. *et al.*, *Malar. J.* 2, 14 (2003). There are other indications, that mefloquine shows stereoselective brain uptake in humans and rats and is a substrate and an inhibitor of the efflux protein P-glycoprotein (Barraud de Lagerie S. *et al.*, *Br. J. Pharmacol.* 141,

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.